Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Limitations of current therapies
11 evidence topics · 11 sources
Summary: limitations of current therapies
In the STEP 1 extension, participants who stopped semaglutide 2.4 mg at week 68 regained 11.6 of 17.3 percentage points of lost weight by week 120. In SURMOUNT-4 (670 randomized participants), those switched from tirzepatide to placebo regained 14% of body weight over 52 weeks, while those who continued tirzepatide lost a further 5.5%. A 2026 meta-analysis of 37 studies (9,341 participants) estimated weight regain of 0.4 kg per month after cessation of weight management medication, with cardiometabolic markers projected to return to baseline within 1.4 years. In commercial claims, 1-year persistence among adults without diabetes was 32.3% for initiators in 2021 and 60.9% for initiators of semaglutide (Wegovy) or tirzepatide (Zepbound) in the first half of 2024; the later study states that shortage resolution “may have improved persistence rates”. In a health-system cohort, 1-year discontinuation was 64.8% in adults without type 2 diabetes. ICER states that “there are few data from clinical trials on outcomes beyond 2-3 years” and that there “remain challenges to accessing highly effective obesity medications”. In a 2025 employer survey, 49% of large employers covered GLP-1 medications for weight loss. In the ADA table of older agents, weight loss from baseline was 5% to 9.8% with active treatment and 1.2% to 5.6% with placebo; phentermine is approved only for short-term use; and metabolic surgery carries perioperative mortality of 0.1% to 0.5% with long-term follow-up by the surgical team falling to 30% at two years.
Weight regain after withdrawal of semaglutide 2.4 mg in the STEP 1 extension
“From week 0 to week 68, mean weight loss was 17.3% (SD: 9.3%) with semaglutide and 2.0% (SD: 6.1%) with placebo. Following treatment withdrawal, semaglutide and placebo participants regained 11.6 (SD: 7.7) and 1.9 (SD: 4.8) percentage points of lost weight, respectively, by week 120, resulting in net losses of 5.6% (SD: 8.9%) and 0.1% (SD: 5.8%), respectively, from week 0 to week 120.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cardiometabolic improvements seen from week 0 to week 68 with semaglutide reverted towards baseline at week 120 for most variables.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Weight regain after withdrawal of tirzepatide in SURMOUNT-4
“After 36 weeks of open-label maximum tolerated dose of tirzepatide (10 or 15 mg), adults (n = 670) with obesity or overweight (without diabetes) experienced a mean weight reduction of 20.9%. From randomization (at week 36), those switched to placebo experienced a 14% weight regain and those continuing tirzepatide experienced an additional 5.5% weight reduction during the 52-week double-blind period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rate of weight regain after cessation of weight management medications
“Of the 9288 titles screened, 37 studies (63 intervention arms, 9341 participants) were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The average monthly rate of weight regain was 0.4 kg (95% confidence interval (CI) 0.3 to 0.5) (mixed model 0.3 kg (0.2 to 0.4) monthly v control in RCTs). All cardiometabolic markers were projected to return to baseline within 1.4 years after the cessation of WMM. Weight regain was faster after WMM than after BWMP (by 0.3 kg (0.22 to 0.34) monthly), independent of initial weight loss.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Real-world persistence and adherence in commercially insured adults without diabetes
“Overall, GLP-1 persistence was 46.3% at 180 days and 32.3% at 1 year. The highest and lowest persistence rates at 1 year were observed for semaglutide (Ozempic) at 47.1% and liraglutide (Saxenda) 19.2%, respectively. Average PDC during the 1-year assessment was 51.0% with 27.2% adherent to therapy and 11.1% switched GLP-1 drugs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Persistence trend by year of initiation and drug shortages
“Across the index years, 1-year persistence increased from 33.2% in 2021 to 60.9% in 1H 2024.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For tirzepatide, 1-year persistence rates in 2023 and 1H 2024 (the only years the product was available) were 64.0% and 64.8%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“GLP-1RA product shortage resolution may have improved persistence rates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Discontinuation in adults with obesity without type 2 diabetes
“Patients with obesity only had a higher prevalence of discontinuation at 12 months vs those with T2D only and those with both (50.3% vs 35.8% and 34.2%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One-year discontinuation was significantly higher for patients without type 2 diabetes (64.8% [95% CI, 64.4%-65.2%]) compared with those with type 2 diabetes (46.5% [95% CI, 46.2%-46.9%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“moderate or severe incident gastrointestinal adverse events were associated with a higher hazard of discontinuation (with type 2 diabetes: HR, 1.38 [95% CI, 1.31-1.45]; without type 2 diabetes: HR, 1.19 [95% CI, 1.12-1.27]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote